To test the ability of AzadC 1 and cAzadC 2 to deplete the DNMT pool, we decided to use the AML cell line MOLM‐13 as a model system, since AzadC 1 is primarily applied in the clinic against AML and myelodysplastic syndrome. The gene discussed is DNMT1; the disease is acute myeloid leukemia.